Free Cash Flow Build Up

Adaptimmune Therapeutics PLC

Adaptimmune Therapeutics PLC (ADAP)

$4.53
0.13 (+2.95%)
Year
A/P
2015
Actual
2016
Actual
2017
Actual
2018
Actual
2019
Actual
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
Revenue 8.9814.2037.8359.511.121.642.393.495.097.43
EBITDA -21.32-66.29-62.03-86.83-126.13-40.14-58.57-85.48-124.75-182.07
EBIT -22.57-69.58-67.46-94.64-134.14-42.68-62.29-90.91-132.68-193.63
Tax Rate 0.24%-1.26%-0.65%-0.52%-0.18%-0.47%-0.47%-0.47%-0.47%-0.47%
EBIAT -22.51-70.45-67.89-95.14-134.38-42.89-62.59-91.34-133.31-194.55
Depreciation 1.253.295.427.818.012.553.725.437.9211.56
Accounts Receivable --0.741.27-17.95-2.5114.47-2.85-4.15-6.06-8.85
Inventories ----------
Accounts Payable -3.47-2.97-4.292.27-3.861.151.682.453.57
Capital Expenditure -9.84-12.79-25.01-4.71-3.07-1.79-2.62-3.82-5.57-8.14
UFCF -31.11-77.22-89.18-114.28-129.68-31.51-63.19-92.21-134.57-196.40
WACC
PV UFCF -37.98-63.19-76.52-92.67-112.22
SUM PV UFCF -263.43